This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Efficacy and safety of guselkumab, an anti-interle...
Journal

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p

Read time: 1 mins
Published:1st Mar 2017
Author: Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al.
Availability: Free full text
Ref.:J Am Acad Dermatol. 2017r;76(3):418-431.
DOI:10.1016/j.jaad.2016.11.042
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest